Background: Identifying factors associated with early post-discharge outpatient care is crucial to prevent relapse and suicide in patients with schizophrenia. This study aimed to investigate factors associated with receiving follow-up care within seven days after hospital discharge among patients with schizophrenia. Methods: This nationwide population-based study was conducted using data from the National Health Insurance Claim Database of South Korea. All patients aged ≥ 18 years, newly admitted to the hospital with schizophrenia between January 1, 2017, and December 31, 2018, were included. The outcome of interest was the receipt of outpatient follow-up care within seven days of hospital discharge. Patients’ general characteristics and healthcare services were included as independent variables. A generalized estimating equation model was used to examine factors associated with the outcome. Results: Of 17,565 patients with schizophrenia, 37.6% received outpatient follow-up care within seven days after hospital discharge. Patients who were older and male were less likely to receive follow-up care seven days after discharge. Patients with prior psychiatric outpatient care to their index admission were more likely to receive follow-up care than those without prior outpatient care. A longer hospital stay significantly decreased the likelihood of receiving outpatient follow-up. However, comorbid alcohol use disorder was not associated with receiving follow-up care within seven days of discharge. Conclusion This study highlights the need to ensure continuity of care for patients with schizophrenia during discharge planning, with particular attention to vulnerable patients.

Background: Identifying factors associated with early post-discharge outpatient care is crucial to prevent relapse and suicide in patients with schizophrenia. This study aimed to investigate factors associated with receiving follow-up care within seven days after hospital discharge among patients with schizophrenia. Methods: This nationwide population-based study was conducted using data from the National Health Insurance Claim Database of South Korea. All patients aged ≥ 18 years, newly admitted to the hospital with schizophrenia between January 1, 2017, and December 31, 2018, were included. The outcome of interest was the receipt of outpatient follow-up care within seven days of hospital discharge. Patients’ general characteristics and healthcare services were included as independent variables. A generalized estimating equation model was used to examine factors associated with the outcome. Results: Of 17,565 patients with schizophrenia, 37.6% received outpatient follow-up care within seven days after hospital discharge. Patients who were older and male were less likely to receive follow-up care seven days after discharge. Patients with prior psychiatric outpatient care to their index admission were more likely to receive follow-up care than those without prior outpatient care. A longer hospital stay significantly decreased the likelihood of receiving outpatient follow-up. However, comorbid alcohol use disorder was not associated with receiving follow-up care within seven days of discharge. Conclusion This study highlights the need to ensure continuity of care for patients with schizophrenia during discharge planning, with particular attention to vulnerable patients.

Background: Identifying factors associated with early post-discharge outpatient care is crucial to prevent relapse and suicide in patients with schizophrenia. This study aimed to investigate factors associated with receiving follow-up care within seven days after hospital discharge among patients with schizophrenia. Methods: This nationwide population-based study was conducted using data from the National Health Insurance Claim Database of South Korea. All patients aged ≥ 18 years, newly admitted to the hospital with schizophrenia between January 1, 2017, and December 31, 2018, were included. The outcome of interest was the receipt of outpatient follow-up care within seven days of hospital discharge. Patients’ general characteristics and healthcare services were included as independent variables. A generalized estimating equation model was used to examine factors associated with the outcome. Results: Of 17,565 patients with schizophrenia, 37.6% received outpatient follow-up care within seven days after hospital discharge. Patients who were older and male were less likely to receive follow-up care seven days after discharge. Patients with prior psychiatric outpatient care to their index admission were more likely to receive follow-up care than those without prior outpatient care. A longer hospital stay significantly decreased the likelihood of receiving outpatient follow-up. However, comorbid alcohol use disorder was not associated with receiving follow-up care within seven days of discharge. Conclusion This study highlights the need to ensure continuity of care for patients with schizophrenia during discharge planning, with particular attention to vulnerable patients.

Background: Identifying factors associated with early post-discharge outpatient care is crucial to prevent relapse and suicide in patients with schizophrenia. This study aimed to investigate factors associated with receiving follow-up care within seven days after hospital discharge among patients with schizophrenia. Methods: This nationwide population-based study was conducted using data from the National Health Insurance Claim Database of South Korea. All patients aged ≥ 18 years, newly admitted to the hospital with schizophrenia between January 1, 2017, and December 31, 2018, were included. The outcome of interest was the receipt of outpatient follow-up care within seven days of hospital discharge. Patients’ general characteristics and healthcare services were included as independent variables. A generalized estimating equation model was used to examine factors associated with the outcome. Results: Of 17,565 patients with schizophrenia, 37.6% received outpatient follow-up care within seven days after hospital discharge. Patients who were older and male were less likely to receive follow-up care seven days after discharge. Patients with prior psychiatric outpatient care to their index admission were more likely to receive follow-up care than those without prior outpatient care. A longer hospital stay significantly decreased the likelihood of receiving outpatient follow-up. However, comorbid alcohol use disorder was not associated with receiving follow-up care within seven days of discharge. Conclusion This study highlights the need to ensure continuity of care for patients with schizophrenia during discharge planning, with particular attention to vulnerable patients.

Background: Psoriasis is a chronic inflammatory skin disease. Despite the current focus on T cells in the pathogenesis of psoriasis, keratinocytes within the psoriatic epidermis are also abnormal in many respects including excessive production of antimicrobial peptides (AMPs). Recently, several studies have used imiquimod (IMQ)- and interleukin (IL)-23-induced mouse models to explore the immunological significance of psoriasis. However, the expression of AMPs in these models remains unclear. Objective: In this study, we evaluated the protein and mRNA expression of AMPs, including cathelicidin-related antimicrobial peptides (CRAMP), mouse β-defensin 3 (mBD3), and psoriasin (S100 calcium-binding protein A7, S100A7) in IMQ- and IL-23-induced psoriasiform mouse models. In addition, we investigated whether ustekinumab, an inhibitor of IL-12 and IL-23, reduces the expression levels of AMPs in these mouse models. Methods: We used IMQ- and IL-23-induced psoriasiform mouse models. Gene and protein expression levels of AMPs were evaluated using quantitative real-time polymerase chain reaction and immunofluorescence staining, respectively. Results: We found that the protein and mRNA expression levels of CRAMP, mBD3, and S100A7 were increased in both mouse models. Ustekinumab decreased AMP expression levels in the two mouse models. Conclusion These data showed that the elevated expression of AMPs in the epidermis decreased following ustekinumab treatment in both psoriasiform mouse models. Therefore, AMP expression levels may be used as an indicator of treatment efficacy.

Background: School-aged children born very preterm have been suggested to have worse cognitive and behavioral outcomes than children born full-term. Executive function (EF) is a higher level of cognitive function related to academic achievement. The present study aimed to evaluate the cognitive (including EF) and behavioral outcomes of Korean children born extremely preterm (EP) and to analyze any biological or socioeconomic risk factors for poor cognitive outcomes in this population. Methods: A total of 71 infants weighing < 1,000 g at birth or born before 30 weeks of gestation (EP group) who were admitted to the neonatal intensive care unit from 2008 to 2009 were included in this study and compared with 40 term-birth controls. The Korean Wechsler Intelligence Scale for Children-Fourth Edition, Advanced Test of Attention (ATA), Stroop test, Children's Color Trails Test (CCTT), and Wisconsin Card Sorting Test (WCST) were used.Additionally, the Korean Child Behavior Checklist (K-CBCL) and Korean ADHD Rating Scale (K-ARS) were completed. Perinatal and demographic data were collected and analyzed. Results: The mean full-scale intelligence quotient (FSIQ) score in the EP group was significantly lower than that of the term control group (89.1 ± 18.3 vs. 107.1 ± 12.7; P < 0.001).In the EP group, 26 (37%) children had an FSIQ score below 85, compared to only one child (3%) in the control group. Furthermore, the EP group showed significantly worse EF test results (ATA, Stroop test, CCTT, WCST). Except for the higher social immaturity subscore in the EP group, the K-CBCL and K-ARS scores were not different between the two groups. EP children who received laser treatment for retinopathy of prematurity (ROP) had an 8.8-fold increased risk of a low FSIQ score, and a 1-point increase in the discharge weight Z-score decreased the risk of a low FSIQ score by approximately half in this EP cohort. Conclusion This is the first Korean study to investigate the cognitive and behavioral outcomes of school-aged children born EP. In the study cohort, EP children exhibited significantly lower FSIQ scores and EF than their full-term peers, and 37% of them had cognitive problems. Nonetheless, except for social immaturity, the behavioral problems werenot different in EP children. Severe ROP and low discharge weight Z-score were identified as independent risk factors for low FSIQ score after adjusting for birth weight.

Background: School-aged children born very preterm have been suggested to have worse cognitive and behavioral outcomes than children born full-term. Executive function (EF) is a higher level of cognitive function related to academic achievement. The present study aimed to evaluate the cognitive (including EF) and behavioral outcomes of Korean children born extremely preterm (EP) and to analyze any biological or socioeconomic risk factors for poor cognitive outcomes in this population. Methods: A total of 71 infants weighing < 1,000 g at birth or born before 30 weeks of gestation (EP group) who were admitted to the neonatal intensive care unit from 2008 to 2009 were included in this study and compared with 40 term-birth controls. The Korean Wechsler Intelligence Scale for Children-Fourth Edition, Advanced Test of Attention (ATA), Stroop test, Children's Color Trails Test (CCTT), and Wisconsin Card Sorting Test (WCST) were used.Additionally, the Korean Child Behavior Checklist (K-CBCL) and Korean ADHD Rating Scale (K-ARS) were completed. Perinatal and demographic data were collected and analyzed. Results: The mean full-scale intelligence quotient (FSIQ) score in the EP group was significantly lower than that of the term control group (89.1 ± 18.3 vs. 107.1 ± 12.7; P < 0.001).In the EP group, 26 (37%) children had an FSIQ score below 85, compared to only one child (3%) in the control group. Furthermore, the EP group showed significantly worse EF test results (ATA, Stroop test, CCTT, WCST). Except for the higher social immaturity subscore in the EP group, the K-CBCL and K-ARS scores were not different between the two groups. EP children who received laser treatment for retinopathy of prematurity (ROP) had an 8.8-fold increased risk of a low FSIQ score, and a 1-point increase in the discharge weight Z-score decreased the risk of a low FSIQ score by approximately half in this EP cohort. Conclusion This is the first Korean study to investigate the cognitive and behavioral outcomes of school-aged children born EP. In the study cohort, EP children exhibited significantly lower FSIQ scores and EF than their full-term peers, and 37% of them had cognitive problems. Nonetheless, except for social immaturity, the behavioral problems werenot different in EP children. Severe ROP and low discharge weight Z-score were identified as independent risk factors for low FSIQ score after adjusting for birth weight.

Objective: Recent innovations in biology are boosting gene and cell therapy, but monitoring the response to these treatments is difficult. The purpose of this study was to find an MRI-reporter gene that can be used to monitor gene or cell therapy and that can be delivered without a viral vector, as viral vector delivery methods can result in long-term complications. Materials and Methods: CMV promoter-human organic anion transporting polypeptide 1B3 (CMV-hOATP1B3) cDNA or CMV-blank DNA (control) was transfected into HEK293 cells using Lipofectamine. OATP1B3 expression was confirmed by western blotting and confocal microscopy. In vitro cell phantoms were made using transfected HEK293 cells cultured in various concentrations of gadoxetic acid for 24 hours, and images of the phantoms were made with a 9.4T micro-MRI. In vivo xenograft tumors were made by implanting HEK293 cells transfected with CMV-hOATP1B3 (n = 4) or CMV-blank (n = 4) in 8-week-old male nude mice, and MRI was performed before and after intravenous injection of gadoxetic acid (1.2 μL/g). Results: Western blot and confocal microscopy after immunofluorescence staining revealed that only CMV-hOATP1B3-transfected HEK293 cells produced abundant OATP1B3, which localized at the cell membrane. OATP1B3 expression levels remained high through the 25th subculture cycle, but decreased substantially by the 50th subculture cycle. MRI of cell phantoms showed that only the CMV-hOATP1B3-transfected cells produced a significant contrast enhancement effect. In vivo MRI of xenograft tumors revealed that only CMV-hOATP1B3-transfected HEK293 tumors demonstrated a T1 contrast effect, which lasted for at least 5 hours. Conclusion The human endogenous OATP1B3 gene can be non-virally delivered into cells to induce transient OATP1B3 expression, leading to gadoxetic acid-mediated enhancement on MRI. These results indicate that hOATP1B3 can serve as an MRI-reporter gene while minimizing the risk of long-term complications.

Background/Aims: The Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST (mRECIST) criteria have been used to assess treatment responses for hepatocellular carcinoma (HCC) patients. We investigated which criteria provides better survival predictions in HCC patients treated with transarterial radioembolization (TARE). Methods: In total, 102 patients with unresectable intrahe-patic HCC, who were treated with TARE between 2012 and 2017, were reviewed retrospectively. The treatment response after TARE was evaluated at 1, 3, and 6 months by the mRE-CIST and RECIST 1.1. Responders were defined as patients with complete or partial responses by each criterion. Results: The median age of 83 men and 19 women was 64.3 years.The median alpha-fetoprotein and des-gamma-carboxy pro-thrombin levels were 37.1 ng/mL and 1,780.0 mAU/mL, re-spectively. The median maximal tumor size was 8.3 cm, and multiple tumors were observed in 36 patients (35.3%). Dur-ing the follow-up period (median, 20.7 months), 21 patients (20.6%) died, with a mean survival time of 55.5 months. The cumulative survival rate was 96.1% at 6 months and 89.3% at 12 months. Responders, defined by the mRECIST at 1, 3, and 6 months after TARE, showed better survival outcomes than nonresponders (hazard ratio [HR]=5.736, p=0.008 at 1 month; HR=3.145, p=0.022 at 3 months, and HR=2.887, p=0.061 at 6 months). The survival rates of responders and nonresponders defined by the RECIST 1.1 were similar (all p>0.05). Conclusions Response evaluations that use the mRECIST provide more accurate prognoses than those that use the RECIST 1.1 in HCC patients treated with TARE.